# ZZedc Unified Regulatory Compliance Implementation Roadmap

**Comprehensive Plan: GDPR + FDA + CRF Design Features**

**Date**: December 2025
**Version**: 1.0
**Status**: Master implementation roadmap combining all regulatory requirements

---

## EXECUTIVE SUMMARY

This document consolidates:
- **GDPR Compliance Requirements** (13 features, 65/100 current score)
- **FDA Compliance Requirements** (9 features, 35-40/100 current score)
- **CRF Design Best Practices** (10 features, 60-70% capability)

Into a **unified implementation roadmap** with coordinated phases, shared dependencies, and clear resource allocation.

### Bottom Line

**To achieve full regulatory compliance for international pharmaceutical trials:**
- **Timeline**: 20-24 weeks (5-6 months)
- **Team**: 2-3 full-time developers
- **Phases**: 5 phases + integration testing
- **Outcome**: FDA-ready + GDPR-compliant EDC system with enterprise-grade CRF design

---

## PART 1: FEATURE INVENTORY & CATEGORIZATION

### 1.1 All Regulatory Features (32 Total)

#### GDPR Features (13)
| # | Feature | Type | Current | Gap |
|---|---------|------|---------|-----|
| G1 | Data Encryption at Rest (SQLCipher) | CRITICAL | âŒ None | 3-4 wks |
| G2 | Data Encryption in Transit (HTTPS/TLS) | CRITICAL | âŒ Ops work | 1 day |
| G3 | Data Subject Access Request (DSAR) | CRITICAL | ğŸŸ¡ UI exists | 2-3 wks |
| G4 | Right to Rectification | CRITICAL | ğŸŸ¡ UI exists | 1 wk |
| G5 | Right to Erasure (with legal hold exception) | CRITICAL | âŒ None | 2 wks |
| G6 | Right to Restrict Processing | CRITICAL | âŒ None | 1 wk |
| G7 | Right to Data Portability | CRITICAL | ğŸŸ¡ UI exists | 1-2 wks |
| G8 | Right to Object | CRITICAL | ğŸŸ¡ UI exists | 1 wk |
| G9 | Consent Withdrawal | CRITICAL | âŒ None | 1 wk |
| G10 | Consent Management System | CRITICAL | ğŸŸ¡ Schema designed | 2-3 wks |
| G11 | Data Retention Enforcement | HIGH | âŒ None | 2 wks |
| G12 | Privacy Impact Assessment Tool | HIGH | âŒ None | 3-4 wks |
| G13 | Breach Notification Workflow | HIGH | âŒ None | 2-3 wks |

**GDPR Total Effort**: 5-6 weeks (with 1-2 developers)

---

#### FDA Features (9)
| # | Feature | Type | Current | Gap |
|---|---------|------|---------|-----|
| F1 | System Validation (IQ/OQ/PQ) | CRITICAL | âŒ None | 2-3 wks |
| F2 | Protocol Compliance Monitoring | CRITICAL | âŒ None | 3-4 wks |
| F3 | Enhanced Data Correction Workflow | CRITICAL | âš ï¸ Partial | 2-3 wks |
| F4 | Study Reconciliation & Closeout | HIGH | âŒ None | 3-4 wks |
| F5 | Adverse Event (AE/SAE) Management | CRITICAL | âŒ None | 3-4 wks |
| F6 | Electronic Signatures (e-Sig) | CRITICAL | ğŸŸ¡ Designed | 2-3 wks |
| F7 | Change Control System | HIGH | ğŸŸ¡ Designed | 2-3 wks |
| F8 | Backup/Recovery Procedures | HIGH | âš ï¸ Partial | 1-2 wks |
| F9 | Regulatory Submission Package | HIGH | âŒ None | 3-4 wks |

**FDA Total Effort**: 8-10 weeks (with 2-3 developers)

---

#### CRF Design Features (10)
| # | Feature | Type | Current | Gap |
|---|---------|------|---------|-----|
| C1 | CRF Completion Guidelines (CCG) Generator | CRITICAL | âŒ None | 2-3 wks |
| C2 | CRF Template Library (10-15 forms) | CRITICAL | âŒ None | 3-4 wks |
| C3 | CRF Version Control & Change Log | CRITICAL | âŒ None | 2-3 wks |
| C4 | CRF Design Review Workflow | CRITICAL | âŒ None | 2-3 wks |
| C5 | Master Field Library (Standardization) | CRITICAL | âŒ None | 2-3 wks |
| C6 | Advanced Validation Rules | HIGH | âš ï¸ Planned (DSL) | 3-4 wks |
| C7 | Protocol-CRF Linkage System | HIGH | âŒ None | 3-4 wks |
| C8 | Conditional Logic & Dependencies | HIGH | âš ï¸ Basic | 2-3 wks |
| C9 | Calculated/Derived Fields | HIGH | âš ï¸ Partial | 2-3 wks |
| C10 | WYSIWYG CRF Designer | MEDIUM | âš ï¸ Basic | 3-4 wks |

**CRF Design Total Effort**: 4-5 months (with 2-3 developers)
*(Note: Can be parallelized with FDA/GDPR work)*

---

### 1.2 Feature Dependencies & Interactions

**Shared Dependencies**:
```
Data Encryption (G1, G2)
â”œâ”€â”€ Needed by: G3 (DSAR export), G5 (Erasure), G7 (Portability)
â”œâ”€â”€ Needed by: F1 (System Validation - security requirement)
â”œâ”€â”€ Needed by: F3 (Data Correction - secure audit trail)
â””â”€â”€ Priority: CRITICAL - must implement first

Audit Trail System (Existing âœ…)
â”œâ”€â”€ Supports: All GDPR features (F3, F4, F6, F7, F8)
â”œâ”€â”€ Supports: All FDA features (F1, F3, F6, F7, F8)
â”œâ”€â”€ Supports: CRF tracking (C1, C3, C4)
â””â”€â”€ Already implemented - leverage existing

Version Control System (C3)
â”œâ”€â”€ Needed by: GDPR (G5 - track consent/processing changes)
â”œâ”€â”€ Needed by: FDA (F2, F7 - protocol/form versions)
â”œâ”€â”€ Needed by: CRF (C1, C3, C4 - form versioning)
â””â”€â”€ Implement early - used by many features

User Access Control (Existing âœ…)
â”œâ”€â”€ Supports: All privacy-sensitive features
â”œâ”€â”€ Supports: Role-based enforcement
â””â”€â”€ Already implemented - enhance with role definitions

Validation Rules (DSL - Planned âœ…)
â”œâ”€â”€ Needed by: FDA (F3, F5 - data quality)
â”œâ”€â”€ Needed by: CRF (C1, C6, C8 - form validation)
â””â”€â”€ Already planned - coordinate timing

Protocol Integration
â”œâ”€â”€ Needed by: FDA (F1, F2 - protocol compliance)
â”œâ”€â”€ Needed by: CRF (C7 - protocol linkage)
â””â”€â”€ Implement as consolidated feature
```

---

## PART 2: UNIFIED IMPLEMENTATION STRATEGY

### 2.1 Phasing Approach

**Option A: Sequential by Regulation** (23-24 weeks total)
1. Phase 1: GDPR (5-6 weeks)
2. Phase 2: FDA (8-10 weeks)
3. Phase 3: CRF (4-5 weeks)
â†’ Linear, clear scope, but long timeline

**Option B: Parallel by Layer** (20-22 weeks total) â­ RECOMMENDED
1. Phase 1: Foundation (weeks 1-4) â€“ Shared infrastructure
2. Phase 2: GDPR (weeks 3-8) â€“ Parallel with Phase 1
3. Phase 3: FDA (weeks 5-14) â€“ Parallel with Phase 2
4. Phase 4: CRF (weeks 12-19) â€“ Parallel with Phase 3
5. Phase 5: Integration (weeks 19-22) â€“ Cross-cutting validation
â†’ Maximum parallelization, 20% faster, requires coordination

**Option C: Risk-Based Priority** (18-20 weeks) â­ FASTEST
1. Phase 1: Data Encryption + Audit Trail (weeks 1-3)
2. Phase 2: FDA Critical Features (weeks 2-8)
3. Phase 3: GDPR Critical Features (weeks 5-11)
4. Phase 4: CRF Design Features (weeks 8-16)
5. Phase 5: Integration & Testing (weeks 16-20)
â†’ Implement highest-risk items first, best ROI

**RECOMMENDATION**: Use Option C (Risk-Based Priority)
- **Faster to market** (18-20 weeks vs 23-24 weeks)
- **Addresses biggest risks first** (data encryption, FDA system validation)
- **Enables early pharma trial preparation** (FDA features ready by week 8)
- **CRF features can be added incrementally** (forms work now, improvements over time)

---

### 2.2 Unified Roadmap (Risk-Based, 20 Weeks)

#### **Phase 1: Foundation & Critical Infrastructure** (Weeks 1-3)

**Goal**: Implement shared infrastructure needed by all features

**Features Implemented**:
- G1: Data Encryption at Rest (SQLCipher migration)
- G2: Data Encryption in Transit (HTTPS/TLS deployment guidance)
- Enhanced Audit Trail system
- Enhanced version control system

**Effort**: 3 weeks, 2-3 developers
**Output**:
- SQLCipher database with transparent encryption
- Migration scripts for existing data
- HTTPS deployment documentation
- Enhanced version tracking for forms, rules, protocols

**Why First**:
- Everything else depends on secure data storage
- Required for all regulatory compliance
- Foundation for other features

**Dependencies**:
- None (foundation layer)

---

#### **Phase 2: FDA Critical Pathway** (Weeks 2-8, Parallel with Phase 1 finishing)

**Goal**: Make ZZedc FDA-ready for pharmaceutical trials

**Features Implemented**:

**Week 2-3** (Parallel with Phase 1):
- F1: System Validation Framework (IQ/OQ/PQ)
  - IQ checklist auto-generation from package metadata
  - OQ testing framework integration
  - PQ performance testing suite
  - PDF report generation
  - Effort: 2-3 weeks, 2 developers

**Week 3-4**:
- F3: Enhanced Data Correction Workflow
  - Correction request form (before/after comparison)
  - Approval workflow (PI/DM)
  - Audit trail of all states
  - Correction report generation
  - Effort: 2-3 weeks, 1-2 developers

**Week 4-5**:
- F6: Electronic Signatures Implementation
  - e-signature capture (typed signature + PIN)
  - Timestamp + audit trail
  - Signature intent verification
  - Password/PIN validation
  - Effort: 2-3 weeks, 1 developer

**Week 5-7**:
- F2: Protocol Compliance Monitoring
  - Protocol upload & parsing
  - Visit schedule enforcement
  - Assessment completeness tracking
  - Protocol deviation documentation
  - Effort: 3-4 weeks, 2 developers

**Week 7-8**:
- F5: Adverse Event (AE/SAE) Management
  - AE/SAE capture form with MedDRA coding
  - SAE auto-flagging & 24-hour alert
  - Safety reporting (expedited + periodic)
  - Safety dashboard & signal detection
  - Effort: 3-4 weeks, 2 developers

**Total Phase 2**: 8 weeks (overlapping), 2-3 developers full-time
**Output**: FDA Tier 1 features complete (System Validation + Protocol Compliance + AE Management ready)

---

#### **Phase 3: GDPR Critical Pathway** (Weeks 5-11, Parallel with Phase 2)

**Goal**: GDPR-compliant data subject rights (90%+)

**Features Implemented**:

**Week 5-6**:
- G3-G9: Data Subject Rights Implementation (Phased)
  - DSAR (Data Subject Access Request) - Article 15
  - Rectification - Article 16
  - Erasure - Article 17 (with legal hold exception for FDA)
  - Restrict Processing - Article 18
  - Data Portability - Article 20
  - Right to Object - Article 21
  - Effort: 3-4 weeks total (batched), 1-2 developers

**Week 7-8**:
- G10: Consent Management System
  - Consent capture forms (granular: research, data processing, contact)
  - Consent proof (timestamp, IP, user agent, e-signature)
  - Consent withdrawal mechanism
  - Consent audit trail
  - Effort: 2-3 weeks, 1 developer

**Week 9-10**:
- G11: Data Retention Enforcement
  - Retention schedules (protocol-based + GDPR-based)
  - Automatic deletion of expired data
  - Anonymization before deletion (for legal hold)
  - Retention audit trail
  - Effort: 2 weeks, 1 developer

**Week 10-11**:
- G5: Right to Erasure with Legal Hold (FDA Conflict Resolution)
  - Mark data as restricted (Article 18)
  - Anonymize identifiers
  - Retain for regulatory hold
  - Dual-compliance satisfaction
  - Effort: Already included in G3-G9

**Total Phase 3**: 7 weeks (overlapping), 1-2 developers
**Output**: GDPR compliance 90%+ (core data rights implemented)

---

#### **Phase 4: CRF Design Excellence** (Weeks 8-16, Parallel with Phases 2-3)

**Goal**: Enterprise-grade CRF design and management

**Features Implemented**:

**Week 8-9** (Parallel with FDA Phase 2 finishing):
- C1: CRF Completion Guidelines (CCG) Generator
  - Extract field metadata (labels, validation rules, instructions)
  - Auto-generate per-field guidance
  - Export as PDF/Word for printing
  - Embed in UI as tooltip/help text
  - Effort: 2-3 weeks, 1 developer

**Week 10-11**:
- C3: CRF Version Control & Change Log
  - Form versioning (v1.0, v1.1, v2.0)
  - Change logs (who, what, when, why)
  - Approval trails with signatures
  - Retroactive data handling (which version used by which subject)
  - Effort: 2-3 weeks, 1 developer

**Week 12-13**:
- C4: CRF Design Review Workflow
  - Review checklist for Data Manager, Biostatistician, PI, Regulatory
  - Status workflow (DRAFT â†’ IN REVIEW â†’ APPROVED)
  - Inline comments on fields
  - Approval tracking with audit trail
  - Effort: 2-3 weeks, 1 developer

**Week 13-14**:
- C5: Master Field Library (Standardization)
  - Standard field definitions (Subject ID, Visit, Vital Signs, Labs)
  - Validation rules + units + reference ranges
  - Reusable field definitions across forms
  - Enforce consistency
  - Effort: 2-3 weeks, 1 developer

**Week 14-16**:
- C2: CRF Template Library (10-15 Core Templates)
  - Demographics, Vital Signs, Labs, Medical History
  - Medications, Physical Exam, AE, Assessments (MMSE, MoCA, ADAS-cog)
  - Each template includes: field definitions, CCG, validation rules
  - Effort: 3-4 weeks, 2 developers

**Total Phase 4**: 9 weeks (overlapping), 1-2 developers
**Output**: CRF design capability 85%+ (templates, version control, review workflow)

---

#### **Phase 5: Integration, Testing & High-Priority Completions** (Weeks 16-20)

**Goal**: Ensure all components work together, implement remaining HIGH-priority features

**Activities**:

**Week 16-17** (Parallel with Phase 4):
- F4: Study Reconciliation & Closeout
  - Subject reconciliation checklist
  - Data lock procedures
  - Closeout reporting
  - Effort: 2-3 weeks, 1 developer

- F7: Change Control System
  - Change request workflow
  - Impact analysis
  - Version control + rollback
  - Effort: 2-3 weeks, 1 developer

**Week 17-18**:
- G12: Privacy Impact Assessment Tool (DPIA)
  - PIA questionnaire
  - Risk assessment
  - Mitigation tracking
  - Report generation
  - Effort: 3-4 weeks, 1 developer

- G13: Breach Notification Workflow
  - Incident reporting
  - Notification templates
  - Regulatory authority notification (GDPR Article 33-34)
  - Audit trail
  - Effort: 2-3 weeks, 1 developer

**Week 18-20**:
- Integration Testing & Bug Fixes
  - Test all features together
  - Fix integration issues
  - Performance testing
  - Security validation
  - Effort: 2-3 weeks, 1-2 developers

- Documentation & Training
  - Feature documentation
  - Admin guide
  - User training materials
  - SOP templates
  - Effort: 1-2 weeks, 1 developer

**Total Phase 5**: 4-5 weeks, 1-2 developers
**Output**: All features integrated + tested + documented

---

### 2.3 Resource Allocation Over 20 Weeks

```
Timeline (Weeks 1-20):
Week  1  2  3  4  5  6  7  8  9 10 11 12 13 14 15 16 17 18 19 20
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Ph 1: [â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•]
Ph 2:       [â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•]
Ph 3:          [â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•]
Ph 4:              [â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•]
Ph 5:                             [â–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ–ˆâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•]

Developer Allocation:
Week 1-3: 2-3 devs (Foundation)
Week 2-8: 2-3 devs (FDA critical path)
Week 5-11: 1-2 devs (GDPR critical path)
Week 8-16: 1-2 devs (CRF design)
Week 16-20: 1-2 devs (Integration + remaining HIGH-priority)

Average Team Size: 2-3 developers
Peak: Week 5-8 (3 developers, all phases active)
```

---

## PART 3: DETAILED FEATURE ROADMAP BY PRIORITY

### 3.1 CRITICAL Features (Must-Have, Week 1-11)

These features must be implemented to achieve basic regulatory compliance.

| Week | Feature | GDPR/FDA/CRF | Effort | Dev | Dependencies |
|------|---------|--------------|--------|-----|---|
| 1-3 | Data Encryption at Rest | GDPR G1 | 3w | 2 | None |
| 1-3 | HTTPS/TLS Deployment | GDPR G2 | 1d | Ops | None |
| 2-4 | System Validation (IQ/OQ/PQ) | FDA F1 | 2w | 2 | G1 |
| 3-5 | Data Correction Workflow | FDA F3 | 2w | 1 | Audit Trail âœ… |
| 4-6 | Electronic Signatures | FDA F6 | 2w | 1 | Audit Trail âœ… |
| 5-7 | Protocol Compliance | FDA F2 | 3w | 2 | Version Control |
| 5-7 | Adverse Event Management | FDA F5 | 3w | 2 | Validation Rules |
| 5-7 | Data Subject Rights | GDPR G3-G9 | 3w | 1 | G1 |
| 7-9 | Consent Management | GDPR G10 | 2w | 1 | G1 |
| 8-10 | CCG Generator | CRF C1 | 2w | 1 | Version Control |
| 9-11 | CRF Version Control | CRF C3 | 2w | 1 | Version Control |
| 10-12 | Data Retention | GDPR G11 | 2w | 1 | Audit Trail âœ… |

**Critical Path**: Data Encryption â†’ System Validation â†’ Protocol Compliance â†’ AE Management
**Timeline**: 11-12 weeks to achieve FDA Tier 1 + GDPR core rights
**Team**: 2-3 developers

---

### 3.2 HIGH Priority Features (Week 12-18)

Important for regulatory compliance and operational excellence.

| Week | Feature | GDPR/FDA/CRF | Effort | Dev | Depends On |
|------|---------|--------------|--------|-----|---|
| 8-10 | CRF Review Workflow | CRF C4 | 2w | 1 | C3 |
| 10-12 | Master Field Library | CRF C5 | 2w | 1 | C1, C3 |
| 12-14 | CRF Template Library | CRF C2 | 3w | 2 | C4, C5 |
| 13-15 | Study Reconciliation | FDA F4 | 3w | 1 | F2, F3 |
| 14-16 | Change Control | FDA F7 | 2w | 1 | Version Control |
| 15-17 | DPIA Tool | GDPR G12 | 3w | 1 | G1-G11 |
| 16-18 | Breach Notification | GDPR G13 | 2w | 1 | G1-G11 |

**Timeline**: 18 weeks for HIGH priority completion
**Team**: 1-2 developers per phase

---

### 3.3 MEDIUM Priority Features (Week 18-20+)

Nice-to-have features that enhance capability but not blocking.

| Week | Feature | GDPR/FDA/CRF | Effort | Dev | Depends On |
|------|---------|--------------|--------|-----|---|
| 12-14 | Protocol-CRF Linkage | CRF C7 | 3w | 1 | C3, C4 |
| 14-16 | Conditional Logic | CRF C8 | 2w | 1 | Validation DSL |
| 15-17 | Calculated Fields | CRF C9 | 2w | 1 | Validation DSL |
| 17-19 | WYSIWYG Designer | CRF C10 | 3w | 2 | C5, C6 |
| 19-20+ | Regulatory Submission Package | FDA F9 | 3w | 1 | F3, F4, F5, F6 |
| 19-20+ | Backup/Recovery Procedures | FDA F8 | 1w | 1 | G1 |

---

## PART 4: COMPLIANCE MILESTONES & METRICS

### 4.1 Compliance Scoring Over Time

```
Compliance Score Progression:

GDPR Compliance:
Week 0:   65/100 (current) â—â—â—â—â—â—â—â”ˆâ”ˆâ”ˆâ”ˆ
Week 11:  90/100 (phase 3 complete) â—â—â—â—â—â—â—â—â—â”ˆ
Week 20:  98/100 (all done) â—â—â—â—â—â—â—â—â—â—

FDA Compliance:
Week 0:   35-40/100 (current) â—â—â—â—â”ˆâ”ˆâ”ˆâ”ˆâ”ˆâ”ˆ
Week 8:   70/100 (phase 2 done) â—â—â—â—â—â—â—â”ˆâ”ˆâ”ˆ
Week 20:  88/100 (+ remaining HIGH) â—â—â—â—â—â—â—â—â—â”ˆ

CRF Design Capability:
Week 0:   60-70% (current) â—â—â—â—â—â—â”ˆâ”ˆâ”ˆâ”ˆ
Week 12:  80% (phase 4 mid-point) â—â—â—â—â—â—â—â—â”ˆâ”ˆ
Week 16:  90% (phase 4 done) â—â—â—â—â—â—â—â—â—â”ˆ
Week 20:  95%+ (integrated) â—â—â—â—â—â—â—â—â—â—
```

---

### 4.2 Key Milestones

**Milestone 1: Foundation Ready (Week 3)**
- âœ… Data encrypted at rest (SQLCipher)
- âœ… Version control operational
- âœ… Enhanced audit trail
- **Impact**: Secure foundation for all regulatory features

**Milestone 2: FDA Tier 1 Ready (Week 8)**
- âœ… System Validation framework (IQ/OQ/PQ)
- âœ… Protocol Compliance monitoring
- âœ… Data Correction workflow (enhanced)
- âœ… Electronic Signatures
- âœ… AE/SAE management
- **Impact**: **Can conduct FDA-regulated pharmaceutical trials**

**Milestone 3: GDPR Core Ready (Week 11)**
- âœ… All data subject rights (Articles 15-22)
- âœ… Consent management system
- âœ… Data retention enforcement
- âœ… Encryption at rest + transit
- **Impact**: **GDPR-compliant for EU data subjects**

**Milestone 4: CRF Design Ready (Week 16)**
- âœ… CRF templates (10-15 forms)
- âœ… Version control + review workflow
- âœ… CCG generator
- âœ… Master field library
- **Impact**: **Enterprise-grade form design and management**

**Milestone 5: Full Integration (Week 20)**
- âœ… All features working together
- âœ… FDA + GDPR conflict resolution (legal hold)
- âœ… Documentation & training
- âœ… Integration testing complete
- **Impact**: **Production-ready for international pharmaceutical trials**

---

### 4.3 Success Criteria

**FDA Compliance**:
- [ ] System Validation documentation complete (IQ/OQ/PQ)
- [ ] Protocol compliance monitoring prevents out-of-protocol data entry
- [ ] AE/SAE system detects and escalates serious events within 24 hours
- [ ] Electronic signatures enforce authorization & audit trail
- [ ] Data corrections fully traceable with approval workflow
- [ ] Regulatory submission package exportable for IND/NDA/BLA
- **Score Target**: 75-80/100

**GDPR Compliance**:
- [ ] Data subject can request and receive complete data within 30 days
- [ ] Data can be deleted (except for legal holds) within reasonable time
- [ ] Consent is granular and withdrawal works immediately
- [ ] Data retention schedules enforced automatically
- [ ] Encryption at rest + transit verified
- [ ] Privacy Impact Assessments generatable
- [ ] Breach notification workflow operational
- **Score Target**: 95-100/100

**CRF Design Quality**:
- [ ] Form creation time reduced 50% (templates)
- [ ] Data entry error rate reduced 20-30% (validation, guidelines)
- [ ] Form version control prevents mid-trial inconsistencies
- [ ] Design review workflow catches quality issues before deployment
- [ ] CRF/protocol linkage verifiable for FDA submission
- **Score Target**: 90-95%

---

## PART 5: RESOURCE & BUDGET PLANNING

### 5.1 Team Composition (Recommended)

**Lead Developer** (Full-time, 20 weeks)
- Overall architecture & coordination
- Database encryption & security
- FDA system validation framework
- Project management

**Developer 2** (Full-time, 20 weeks)
- FDA features (Protocol compliance, AE management, e-signatures)
- CRF design (Templates, version control)
- Integration testing

**Developer 3** (Full-time, 12 weeks; 50% weeks 13-20)
- GDPR features (Data rights, consent, retention)
- CRF design (Review workflow, master library)
- Documentation & training

**QA/Testing** (Part-time, final 8 weeks)
- Integration testing
- FDA validation testing
- Security/penetration testing
- Performance testing

**DevOps** (Part-time, week 1-3)
- SQLCipher setup & migration
- HTTPS/TLS deployment guidance
- Backup/recovery procedures

**Total Cost Estimate**:
```
Lead Developer:     $200k/year Ã— 5 months = ~$83k
Developer 2:        $160k/year Ã— 5 months = ~$67k
Developer 3:        $160k/year Ã— 3 months = ~$40k
QA Engineer:        $120k/year Ã— 2 months = ~$20k
DevOps (contract):  $150/hour Ã— 40 hours = ~$6k
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Total:              ~$216k (salary + contract)

With overhead (30%): ~$280k
```

---

### 5.2 Risk Management

**High Risks**:

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|-----------|
| SQLCipher migration causes data corruption | Medium | Critical | Test migration with backup, rollback plan |
| Protocol parsing (NLP) unreliable | Medium | High | Manual protocol mapping as fallback, gradual rollout |
| FDA audit trail performance degrades | Low | Critical | Benchmark before/after, optimize indexes |
| Staff underestimates CRF template effort | Medium | Medium | Create 2 templates as POC, adjust estimates |
| Scope creep (more features added mid-project) | High | High | Strict feature gate, Milestone gates, change control |

**Medium Risks**:

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|-----------|
| GDPR/FDA conflict resolution not tested enough | Medium | High | Dedicated test scenarios, legal review |
| e-signature library bugs | Low | High | Use vetted library, thorough testing |
| CRF template library incomplete | Low | Medium | Start with 5 most common, expand post-launch |
| Integration testing discovers major issues | Medium | High | Continuous integration during development |

---

## PART 6: PHASING DECISION MATRIX

### Should We Use Option C (Risk-Based, 20 weeks)?

**Pros**:
- âœ… Fastest timeline (20 weeks vs 23-24 weeks)
- âœ… Addresses biggest risks first (encryption, FDA validation)
- âœ… Enables pharma trials sooner (FDA ready by week 8)
- âœ… Better team morale (visible progress each week)
- âœ… Better ROI (can do pharma trials while building CRF)

**Cons**:
- âŒ Requires careful coordination (3 concurrent phases)
- âŒ More moving parts (higher integration risk)
- âŒ Team must understand all domains

**Recommendation**: â­ **YES, use Option C**

Reasoning:
1. Pharmaceutical trials are higher-value use case (time to market matters)
2. CRF features can be added incrementally (forms work now)
3. Parallelization saves 3-4 weeks
4. Risk-based approach addresses biggest blockers first

---

## PART 7: INTEGRATION STRATEGY

### 7.1 Cross-Feature Integration Points

**Data Encryption Integration**:
- G1 (encryption at rest) required by:
  - G3-G9 (data subject rights - secure data export)
  - F1 (system validation - security requirement)
  - F3 (data correction - secure trails)
  - F5 (AE management - safety data security)

**Version Control Integration**:
- Version system required by:
  - C3 (CRF version tracking)
  - F7 (change control)
  - G5 (legal hold for amendments)
  - F2 (protocol amendment handling)

**Audit Trail Integration**:
- Existing audit trail enhanced for:
  - G3-G9 (DSAR, deletion, rectification tracking)
  - F3 (data correction approval)
  - F6 (e-signature verification)
  - F7 (change control)
  - C4 (CRF review approvals)

**Validation Rules Integration**:
- Validation DSL (already planned) used by:
  - C6 (CRF validation)
  - C8 (conditional logic)
  - F3 (data correction validation)
  - F5 (AE severity validation)

---

### 7.2 Data Flow Integration Example

```
Subject Enrolled in International Pharma Trial
â”œâ”€ Consent captured (G10)
â”‚  â”œâ”€ GDPR consent recorded (consent_log)
â”‚  â””â”€ Audit trail: timestamp, IP, signature
â”œâ”€ CRF form assigned (C2 template + C4 review approved)
â”‚  â”œâ”€ Form version tracked (C3)
â”‚  â”œâ”€ Protocol linked (C7)
â”‚  â””â”€ Completion guidelines shown (C1)
â”œâ”€ Subject visits site at Week 4
â”‚  â”œâ”€ Check visit window (F2 protocol compliance)
â”‚  â”œâ”€ Vital signs collected (C2 template)
â”‚  â”œâ”€ Validation rules applied (C6, C8)
â”‚  â”œâ”€ Data encrypted (G1) before storage
â”‚  â””â”€ Audit trail logged (existing âœ…)
â”œâ”€ Adverse event reported
â”‚  â”œâ”€ AE form presented (C2 template)
â”‚  â”œâ”€ MedDRA coding applied (F5)
â”‚  â”œâ”€ SAE auto-flagged (F5)
â”‚  â”œâ”€ 24-hour escalation (F5)
â”‚  â”œâ”€ Data correction workflow if needed (F3)
â”‚  â””â”€ e-signature for approval (F6)
â”œâ”€ Data quality monitoring
â”‚  â”œâ”€ Query generated (missing data)
â”‚  â”œâ”€ Correction submitted (F3)
â”‚  â”œâ”€ Correction approved + e-signed (F6)
â”‚  â”œâ”€ Version tracking for form (C3)
â”‚  â””â”€ Audit trail updated
â”œâ”€ Study ends, data lock (F4)
â”‚  â”œâ”€ Study reconciliation checklist (F4)
â”‚  â”œâ”€ Data corrections finalized (F3)
â”‚  â”œâ”€ Legal hold enforced (G5 - FDA retention)
â”‚  â”œâ”€ Regulatory submission package generated (F9)
â”‚  â””â”€ Change control documented (F7)
â””â”€ Subject later requests data deletion (G5)
   â”œâ”€ Request verified (identity verification)
   â”œâ”€ Data marked as restricted (G6)
   â”œâ”€ Identifiers anonymized/encrypted
   â”œâ”€ De-identified data retained for regulatory hold
   â”œâ”€ FDA legal hold exception respected
   â”œâ”€ GDPR right to erasure satisfied
   â””â”€ Audit trail of deletion request
```

---

## PART 8: DELIVERY CHECKLIST

### Phase-by-Phase Deliverables

**Phase 1: Foundation (Week 1-3)**
- [ ] SQLCipher integration complete
- [ ] Database migration tested (with rollback)
- [ ] HTTPS/TLS deployment guide documented
- [ ] Enhanced version control system operational
- [ ] Enhanced audit trail logging verified

**Phase 2: FDA Tier 1 (Week 2-8)**
- [ ] IQ/OQ/PQ framework documented
- [ ] System validation checklist auto-generation working
- [ ] Protocol upload & parsing working (MVP)
- [ ] Visit schedule enforcement active
- [ ] Data correction workflow with approval trail
- [ ] e-signature capture & validation working
- [ ] AE/SAE capture form deployed
- [ ] SAE auto-flagging & 24-hour alert working
- [ ] Safety monitoring dashboard operational

**Phase 3: GDPR Tier 1 (Week 5-11)**
- [ ] DSAR (Article 15) fully operational
- [ ] Rectification (Article 16) working
- [ ] Erasure (Article 17) with legal hold exception working
- [ ] Restrict Processing (Article 18) implemented
- [ ] Data Portability (Article 20) exporting FHIR JSON
- [ ] Right to Object (Article 21) working
- [ ] Consent withdrawal (Article 19) immediate
- [ ] Consent management system with granular capture
- [ ] Data retention schedules enforced
- [ ] Retention deletion automation working

**Phase 4: CRF Design (Week 8-16)**
- [ ] CCG generator producing PDF completion guides
- [ ] 10-15 CRF templates in library (demographics, vitals, labs, PE, AE, assessments)
- [ ] CRF version control tracking all changes
- [ ] CRF design review workflow with sign-offs
- [ ] Master field library standardizing across forms
- [ ] Reusable field definitions available to form designers

**Phase 5: Integration & High Priority (Week 16-20)**
- [ ] All features integrated & cross-tested
- [ ] FDA/GDPR conflict resolution verified (legal hold)
- [ ] Study Reconciliation & Closeout workflow complete
- [ ] Change Control system operational
- [ ] DPIA (Privacy Impact Assessment) tool working
- [ ] Breach Notification workflow operational
- [ ] All features documented
- [ ] Training materials created
- [ ] Admin guide written
- [ ] SOP templates provided

---

## PART 9: SUCCESS METRICS & KPIs

### During Implementation

| Metric | Target | How Measured |
|--------|--------|---|
| On-time delivery | 95% of milestones on schedule | Weekly project status |
| Code quality | <1 critical bug per 100 lines | Code review metrics |
| Test coverage | >80% code coverage | Test reports |
| Performance | <100ms response time for forms | Load testing |
| Security | Zero known vulnerabilities | Security audit |

### Post-Implementation

| Metric | Target | How Measured |
|--------|--------|---|
| FDA Compliance Score | 75-80/100 | Compliance audit checklist |
| GDPR Compliance Score | 95-100/100 | GDPR audit checklist |
| CRF Design Quality | 90-95% capability | Feature checklist |
| Form Creation Time | 50% reduction | Time tracking study |
| Data Entry Error Rate | 20-30% reduction | Error log analysis |
| User Satisfaction | >4/5 stars | User survey |
| Pharma Trial Readiness | Support 100+ patient studies | Actual deployments |

---

## PART 10: CONTINGENCY PLANS

### If We Fall Behind Schedule

**Week 8 Slippage Risk** (Phase 2 not complete):
- Option A: Extend Phase 2 by 1-2 weeks (delay FDA readiness)
- Option B: Reduce CRF templates from 15 to 10 (drop less common forms)
- Option C: Push "Backup/Recovery Procedures" (F8) to Phase 5 (medium priority)
- **Recommendation**: Option B (reduce templates, add post-launch)

**Week 11 Slippage Risk** (GDPR not ready):
- Option A: Extend Phase 3 by 1-2 weeks
- Option B: Push "DPIA Tool" (G12) to Phase 5 (high priority but not blocking)
- Option C: Implement DPIA manually using template, automate later
- **Recommendation**: Option C (manual DPIA, auto later, keeps GDPR core rights)

**Week 16 Slippage Risk** (CRF not ready):
- Option A: Extend Phase 4 by 1-2 weeks
- Option B: Reduce template library from 15 to 8 (essential templates only)
- Option C: Use generic forms, templates available in v1.1 release
- **Recommendation**: Option B or C (CRF enhancement, not blocking)

---

## PART 11: POST-LAUNCH ROADMAP

### v1.1 (2-3 months post-launch)

Features to add after core compliance:
- F8: Backup/Recovery Procedures (finalized)
- F9: Regulatory Submission Package (full version with all data types)
- CRF templates: Additional 5-10 domain-specific forms
- C10: WYSIWYG CRF Designer (user-friendly form building)
- Advanced analytics dashboards
- EHR data import capabilities

### v1.2 (4-6 months post-launch)

- C7: Full Protocol-CRF Linkage with amendments
- C8: Advanced conditional logic builder
- C9: Calculated field library (assessment scoring, derived values)
- Validation DSL full implementation (cross-visit, cross-patient rules)
- Patient portal for PRO (Patient-Reported Outcomes) capture
- Multi-language CRF support

---

## SUMMARY TABLE: ALL FEATURES

| # | Feature | Regulation | Phase | Week | Effort | Dev | Critical | Status |
|---|---------|-----------|-------|------|--------|-----|----------|--------|
| 1 | Data Encryption (SQLCipher) | GDPR | 1 | 1-3 | 3w | 2 | YES | ğŸ”´ |
| 2 | HTTPS/TLS | GDPR | 1 | 1-3 | 1d | Ops | YES | ğŸ”´ |
| 3 | System Validation (IQ/OQ/PQ) | FDA | 2 | 2-4 | 2w | 2 | YES | ğŸ”´ |
| 4 | Data Correction Workflow | FDA | 2 | 3-5 | 2w | 1 | YES | ğŸŸ¡ |
| 5 | Electronic Signatures | FDA | 2 | 4-6 | 2w | 1 | YES | ğŸ”´ |
| 6 | Protocol Compliance | FDA | 2 | 5-7 | 3w | 2 | YES | ğŸ”´ |
| 7 | Adverse Event Management | FDA | 2 | 5-7 | 3w | 2 | YES | ğŸ”´ |
| 8 | Data Subject Rights (G3-G9) | GDPR | 3 | 5-7 | 3w | 1 | YES | ğŸ”´ |
| 9 | Consent Management | GDPR | 3 | 7-9 | 2w | 1 | YES | ğŸ”´ |
| 10 | CCG Generator | CRF | 4 | 8-10 | 2w | 1 | YES | ğŸ”´ |
| 11 | CRF Version Control | CRF | 4 | 9-11 | 2w | 1 | YES | ğŸ”´ |
| 12 | Data Retention | GDPR | 3 | 10-12 | 2w | 1 | YES | ğŸ”´ |
| 13 | CRF Review Workflow | CRF | 4 | 8-10 | 2w | 1 | HIGH | ğŸ”´ |
| 14 | Master Field Library | CRF | 4 | 10-12 | 2w | 1 | HIGH | ğŸ”´ |
| 15 | CRF Template Library | CRF | 4 | 12-14 | 3w | 2 | HIGH | ğŸ”´ |
| 16 | Study Reconciliation | FDA | 5 | 13-15 | 3w | 1 | HIGH | ğŸ”´ |
| 17 | Change Control | FDA | 5 | 14-16 | 2w | 1 | HIGH | ğŸ”´ |
| 18 | DPIA Tool | GDPR | 5 | 15-17 | 3w | 1 | HIGH | ğŸ”´ |
| 19 | Breach Notification | GDPR | 5 | 16-18 | 2w | 1 | HIGH | ğŸ”´ |
| 20 | Protocol-CRF Linkage | CRF | 5 | 12-14 | 3w | 1 | MEDIUM | ğŸ”´ |
| 21 | Conditional Logic | CRF | 5 | 14-16 | 2w | 1 | MEDIUM | ğŸ”´ |
| 22 | Calculated Fields | CRF | 5 | 15-17 | 2w | 1 | MEDIUM | ğŸ”´ |
| 23 | WYSIWYG Designer | CRF | 5 | 17-19 | 3w | 2 | MEDIUM | ğŸ”´ |
| 24 | Regulatory Submission Package | FDA | 5 | 19-20+ | 3w | 1 | HIGH | ğŸ”´ |
| 25 | Backup/Recovery Procedures | FDA | 5 | 19-20 | 1w | 1 | HIGH | ğŸ”´ |

---

## FINAL RECOMMENDATION

### Proceed with Risk-Based Priority Implementation (Option C)

**Timeline**: 20 weeks
**Team**: 2-3 developers + QA/DevOps support
**Cost**: ~$280k (all-in with overhead)
**Outcome**:
- âœ… FDA-ready EDC system (Tier 1 complete by week 8)
- âœ… GDPR-compliant (core rights by week 11)
- âœ… Enterprise-grade CRF design (by week 16)
- âœ… Full integration (by week 20)

**Key Success Factors**:
1. Experienced project manager (coordinate 3 concurrent phases)
2. Clear scope management (feature gate at milestones)
3. Continuous integration (catch integration issues early)
4. Regular compliance checkpoints (audit against requirements weekly)
5. Strong documentation (SOP creation during, not after)

**Go-Live Readiness**:
- Week 8: Can begin FDA pharma trial pilots
- Week 11: Can serve GDPR-regulated EU data subjects
- Week 16: Can deploy in international multi-site trials
- Week 20: Production-ready for all regulatory environments

---

**Prepared By**: Claude Code Analysis
**Date**: December 2025
**Status**: Unified regulatory compliance roadmap for ZZedc
